The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models
Corrie Gidding(Radboud University Nijmegen), Peter J. Houghton(King's College London), Tiny G. J. Meeuwsen‐de Boer(University Medical Center Groningen), Richard A. Ashmun(St. Jude Children's Research Hospital), Karen A. Veverka(St. Jude Children's Research Hospital), Willem A. Kamps(Pediatric Oncology Group), Glen S. Germain(St. Jude Children's Research Hospital), Siebold S.N. de Graaf(Royal Hospital for Children), Michael B. Dilling(St. Jude Children's Research Hospital)
Cited by 12
Related Papers
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932
Evidence Based Selection of Housekeeping Genes
|PLoS ONE|2007|772
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599